VRTX · News · 20260817N

Litigation and Legal Risk

VERTEX PHARMACEUTICALS INC / MA · 2026-08-17 · Importance 31 · Surprise 42

Kahn Swick & Foti announced an investigation into the adequacy of the price and process of Vertex’s proposed acquisition of Crinetics Pharmaceuticals. Under the proposed transaction, Crinetics shareholders would receive $85.00 in cash per share. The investigation could create transaction-execution and legal-risk exposure, although the report did not quantify any potential liability or provide a resolution timeframe.

Key facts

• The law firm Kahn Swick & Foti, LLC is investigating the proposed sale of Crinetics Pharmaceuticals to Vertex Pharmaceuticals for adequacy of price and process. source